spacer
home > ebr > spring 2017 > culture clash
PUBLICATIONS
European Biopharmaceutical Review

Culture Clash

Serum has long been an integral media component of cell culture, providing a rich source of diverse nutrients vital for successful in vitro culture. Fetal bovine serum (FBS) is the preferred serum source for cell culture for several reasons. First, FBS is highly accessible and accommodating to most cell types and is therefore the most widely used supplement for mammalian cell culture Ė including human primary cells. Second, it consists of a broad spectrum of components like proteins, growth factors, enzymes and other chemical constituents that make it ideal for promoting cell health and growth. Third, it provides a broad spectrum of utility such as attachment and spreading, detoxifying and transport factors attributed to a serumís complex structure (1,2).

Lot-to-Lot Variability

Although FBS can be utilised across a wide array of cell types from various sources (including multiple different species), one major disadvantage is its lot-to-lot variability, which is also observed in other serum compositions such as human serum albumin (HSA). This variability stems from the numerous natural and chemical components that contribute to its complex structure, which is attributed to the varying conditions and parameters observed during processing and collection. For example, inconsistency in batch sizes; the number and age of animals used; the potential presence of varying amounts of endotoxins; and other pathogen-associated contaminants can all influence each lotís quantitative and qualitative consistency and performance. This necessitates the regular screening of multiple FBS lots prior to purchase in order to maintain a consistent experimental and/or manufacturing output. Additionally, even when the ideal lot has been identified, the culture effects can still vary from one cell type to the next. This impacts the ability to utilise a single lot for multiple applications and poses a challenge for translational and human clinical studies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Since joining Irvine Scientific in 2012, Jessie HT Ni has been leading the R&D team in developing improved CD, ACF culture media for major primary cells and cell lines. She received her PhD in Molecular Biology and post-doctoral training in Immunology from University of Minnesota, US, and also has a Masterís degree in Management of Technology from Carlson School of Management, University of Minnesota.
spacer
Jessie HT Ni
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wickham Laboratories will be on Stand 8 at the 24th Annual Pharmig Conference in the Nottingham Belfry Hotel, November 16th & 17th


More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 Ė 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last yearís figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

ISPPP_2017

19-21 July 2017, Philadelphia, PA, USA

Mark your calendar to attend the premier meeting on state-of-the-art separation, analysis, and characterization methods, much of which is based on HPLC/UHPLC/Mass Spectrometry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement